Dopamine System Dysregulation and the Pathophysiology of Schizophrenia: Insights From the Methylazoxymethanol Acetate Model

Biological Psychiatry

Volumn 81, Issue 1, 2017, Pages 5-8

  Grace, Anthony A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLAZOXYMETHANOL ACETATE; PARVALBUMIN; DOPAMINE;

DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; FACILITATION; HIPPOCAMPUS; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SCHIZOPHRENIA; VENTRAL PALLIDUM; VENTRAL STRIATUM; ANIMAL; BRAIN; DISEASE MODEL; HUMAN; METABOLISM; NERVE CELL; RAT;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; METHYLAZOXYMETHANOL ACETATE; NEURONS; RATS; SCHIZOPHRENIA;

EID: 84954285996     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2015.11.007     Document Type: Note

References (10)

1. 1 Grace, A.A., Dopamine system dysregulation by the hippocampus: Implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology 62 (2012), 1342–1348.
2. 2 Moore, H., Jentsch, J.D., Ghajarnia, M., Geyer, M.A., Grace, A.A., A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: Implications for the neuropathology of schizophrenia. Biol Psychiatry 60 (2006), 253–264.
3. 3 Lodge, D.J., Behrens, M.M., Grace, A.A., A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci 29 (2009), 2344–2354.
4. 4 Lodge, D.J., Grace, A.A., Divergent activation of ventromedial and ventrolateral dopamine systems in animal models of amphetamine sensitization and schizophrenia. Int J Neuropsychopharmacol 15 (2012), 69–76.
5. 5 Allen, P., Chaddock, C.A., Howes, O.D., Egerton, A., Seal, M.L., Fusar-Poli, P., et al. Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis. Schizophr Bull 38 (2012), 1040–1049.
6. 6 Laruelle, M., Abi-Dargham, A., Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies. J Psychopharmacol 13 (1999), 358–371.
7. 7 Gill, K.M., Grace, A.A., Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model. Int J Neuropsychopharmacol 17 (2014), 1609–1619.
8. 8 Gill, K.M., Lodge, D.J., Cook, J.M., Aras, S., Grace, A.A., A novel α5GABAAR positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology 36 (2011), 1903–1911.
9. 9 Gill, K.M., Cook, J.M., Poe, M.M., Grace, A.A., Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. Schizophr Bull 40 (2014), 341–350.
10. 10 Du, Y., Grace, A.A., Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia. Neuropsychopharmacology 38 (2013), 1881–1888.